HK1250213A1 - Wt1抗原肽和免疫調節劑的組合 - Google Patents

Wt1抗原肽和免疫調節劑的組合

Info

Publication number
HK1250213A1
HK1250213A1 HK18107308.2A HK18107308A HK1250213A1 HK 1250213 A1 HK1250213 A1 HK 1250213A1 HK 18107308 A HK18107308 A HK 18107308A HK 1250213 A1 HK1250213 A1 HK 1250213A1
Authority
HK
Hong Kong
Prior art keywords
immunomodulator
combination
antigen peptide
antigen
peptide
Prior art date
Application number
HK18107308.2A
Other languages
English (en)
Inventor
Hideo Takasu
Megumi Nakamura
Masashi Goto
Natsuko Suginobe
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Int Inst Cancer Immunology Inc filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of HK1250213A1 publication Critical patent/HK1250213A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
HK18107308.2A 2015-05-20 2018-06-05 Wt1抗原肽和免疫調節劑的組合 HK1250213A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015103145 2015-05-20
PCT/JP2016/064923 WO2016186177A1 (ja) 2015-05-20 2016-05-19 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用

Publications (1)

Publication Number Publication Date
HK1250213A1 true HK1250213A1 (zh) 2018-12-07

Family

ID=57320344

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18107308.2A HK1250213A1 (zh) 2015-05-20 2018-06-05 Wt1抗原肽和免疫調節劑的組合
HK18108240.1A HK1248546A1 (zh) 2015-05-20 2018-06-27 Wt1抗原肽和免疫調節劑的組合

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18108240.1A HK1248546A1 (zh) 2015-05-20 2018-06-27 Wt1抗原肽和免疫調節劑的組合

Country Status (7)

Country Link
US (1) US20180140691A1 (zh)
EP (1) EP3299028A4 (zh)
JP (4) JP6515182B2 (zh)
CN (1) CN107921106B (zh)
CA (1) CA2986367A1 (zh)
HK (2) HK1250213A1 (zh)
WO (1) WO2016186177A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2907782C (en) 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
AU2016356708B2 (en) 2015-11-20 2022-02-03 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP3549957A4 (en) * 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. WT1-HELPER PEPTIDE AND COMBINATION OF THE SAYING PEPTIDE AND A CANCER ANTIGEN PEPTIDE CONJUGATE
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
IL310079A (en) * 2017-08-28 2024-03-01 Bristol Myers Squibb Co TIM-3 antagonists for the treatment and diagnosis of cancer
LT3691620T (lt) * 2017-10-05 2022-09-26 Fulcrum Therapeutics, Inc. P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
AU2019352354A1 (en) * 2018-10-05 2021-05-13 International Institute Of Cancer Immunology, Inc. Prophylactic or therapeutic drug for benign tumor
US20220168408A1 (en) * 2019-04-10 2022-06-02 Slsg Limited Llc Multi-valent immunotherapy composition and methods of use for treating wt1-positive cancers
WO2021021924A1 (en) * 2019-07-29 2021-02-04 Huang Cai Gu Formulation of antibody based drugs for treating lung cancer by inhalation
CN114945383A (zh) 2019-12-10 2022-08-26 住友制药株式会社 肽乳液制剂的调制方法
US20230255978A1 (en) * 2020-05-12 2023-08-17 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20230163364A (ko) * 2021-03-31 2023-11-30 셀레론 테라퓨틱스 리미티드 백신 보조제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511538C (en) * 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
DE602004023476D1 (de) * 2003-01-15 2009-11-19 Chugai Pharmaceutical Co Ltd Dimerisiertes peptid
CA2520172C (en) * 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
AU2004255470B2 (en) * 2003-07-10 2010-08-19 Cytos Biotechnology Ag Packaged virus-like particles
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
MX2008013993A (es) * 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
JP5427027B2 (ja) * 2006-05-03 2014-02-26 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
DK2370593T3 (en) * 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
BR112012026227A2 (pt) * 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
CN103157108B (zh) * 2011-12-13 2016-01-20 宁云山 免疫调节剂组合物及其药物组合物和应用
CA2858876A1 (en) * 2011-12-15 2013-06-20 The University Of Chicago Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN103830211A (zh) * 2012-11-27 2014-06-04 上海曼克尔瑞生物医药技术有限公司 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用
RU2687026C2 (ru) * 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
KR102363191B1 (ko) * 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
CA2907782C (en) * 2013-03-29 2021-01-05 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害

Also Published As

Publication number Publication date
JP6515182B2 (ja) 2019-05-15
HK1248546A1 (zh) 2018-10-19
EP3299028A1 (en) 2018-03-28
US20180140691A1 (en) 2018-05-24
CA2986367A1 (en) 2016-11-24
CN107921106A (zh) 2018-04-17
JP2022000454A (ja) 2022-01-04
JP2019135251A (ja) 2019-08-15
WO2016186177A1 (ja) 2016-11-24
JP6956967B2 (ja) 2021-11-02
JP7253210B2 (ja) 2023-04-06
EP3299028A4 (en) 2019-02-27
JP2020075934A (ja) 2020-05-21
JPWO2016186177A1 (ja) 2018-04-12
JP6713160B2 (ja) 2020-06-24
CN107921106B (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
HK1248546A1 (zh) Wt1抗原肽和免疫調節劑的組合
IL249032A0 (en) ras inhibitory peptides and their uses
IL284236A (en) Modifications and uses of conotoxin peptides
HK1251979A1 (zh) 肽組合物和使用方法
GB201621707D0 (en) Synthesis and use of amino lipids
IL259096A (en) Peptides and methods of treating endometriosis using the same
IL287985A (en) A peptide derived from koc1 and a component containing it
IL284792A (en) Peptide derivative - DEPDC1 and a component containing it
IL250215B (en) A peptide derived from cdca1 and a component containing it
IL251289B (en) New peptide derivatives and their use
PT3430390T (pt) Origem molecular da alergia
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL247448A0 (en) Peptides and methods of use
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
SG11201610918RA (en) Peptides and uses thereof
GB201401673D0 (en) Esculentin-2CHa peptide and analogues thereof
AU2015901160A0 (en) Immunomodulatory peptides and methods of use
GB201504211D0 (en) Use of peptides